deltatrials

Carcinoma, hepatocellular Trials in Taipei, Taiwan

Conditions / Carcinoma, hepatocellular / Taipei, Taiwan

Carcinoma, hepatocellular is a medical condition with active clinical research programs worldwide.

44 total trials for this combination

Showing top 10 of 44 trials

Trials

NCT ID Title Status Phase
NCT04246177 Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012) COMPLETED
NCT01774344 Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma COMPLETED PHASE3
NCT03434379 A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma COMPLETED PHASE3
NCT04008797 A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor ACTIVE_NOT_RECRUITING PHASE1/PHASE2
NCT03713593 Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002) COMPLETED PHASE3
NCT00855218 A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC). COMPLETED PHASE2
NCT00901901 Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma COMPLETED PHASE3
NCT04246177 Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012) COMPLETED
NCT00692770 Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM) COMPLETED PHASE3
NCT01009593 Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) TERMINATED PHASE3

Related Pages